Thus, microenvironmental sources of extracellular S1P can contribute to the drug-resistance of MM cells and provide another reason why anti-S1P metabolism therapeutics may be useful and argue the importance of testing these in vivo, particularly for re-sensitization to other therapeutics. The gene discussed is MBTPS1; the disease is Miyoshi myopathy.